Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly EBITDA of -$50.0 million in Q1 2026, down 24.72% quarter-over-quarter from -$40.0 million in Q4 2025, and down 22.44% year-over-year from -$64.4 million in Q1 2025.
Vanda Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- In Q1 2026, EBITDA fell 22.44% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$159.2 million (down 122.6% YoY), while the FY2025 annual figure was -$150.1 million, down 277.43% from the prior year.
- EBITDA came in at -$50.0 million for Q1 2026 at Vanda Pharmaceuticals, down from -$40.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $6.9 million in Q4 2022 to a low of -$50.0 million in Q1 2026.
- A 5-year average of -$14.4 million and a median of -$9.0 million in 2024 frame the typical range for EBITDA.
- Across the five-year window, EBITDA jumped 131.24% in 2023 and plunged 493.42% in 2024, its largest moves.
- Vanda Pharmaceuticals' EBITDA stood at $6.9 million in 2022, then plunged by 199.9% to -$6.9 million in 2023, then sank by 45.41% to -$10.0 million in 2024, then sank by 299.81% to -$40.0 million in 2025, then slipped by 24.72% to -$50.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$50.0 million, -$40.0 million, and -$31.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -49.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.95 Mn |
| Dec 31, 2025 | -40.05 Mn |
| Sep 30, 2025 | -30.98 Mn |
| Jun 30, 2025 | -38.24 Mn |
| Mar 31, 2025 | -40.80 Mn |
| Dec 31, 2024 | -10.02 Mn |
| Sep 30, 2024 | -10.78 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Mar 31, 2024 | -9.03 Mn |
| Dec 31, 2023 | -6.89 Mn |
| Sep 30, 2023 | -5.80 Mn |
| Jun 30, 2023 | -2.64 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 6.90 Mn |
| Sep 30, 2022 | 4.21 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Mar 31, 2022 | -7.35 Mn |
| Dec 31, 2021 | 9.01 Mn |
| Sep 30, 2021 | 11.16 Mn |
| Jun 30, 2021 | 12.71 Mn |
| Mar 31, 2021 | 10.69 Mn |
| Dec 31, 2020 | 10.81 Mn |
| Sep 30, 2020 | 8.09 Mn |
| Jun 30, 2020 | 9.51 Mn |
| Mar 31, 2020 | 226,000.00 |
| Dec 31, 2019 | 4.62 Mn |
| Sep 30, 2019 | 11.11 Mn |
| Jun 30, 2019 | 10.24 Mn |
| Mar 31, 2019 | -1.76 Mn |
| Dec 31, 2018 | 9.52 Mn |
| Sep 30, 2018 | 6.58 Mn |
| Jun 30, 2018 | 4.27 Mn |
| Mar 31, 2018 | 2.79 Mn |
| Dec 31, 2017 | -1.85 Mn |
| Sep 30, 2017 | -4.58 Mn |
| Jun 30, 2017 | -1.92 Mn |
| Mar 31, 2017 | -7.91 Mn |
| Dec 31, 2016 | -654,000.00 |
| Sep 30, 2016 | -653,000.00 |
| Jun 30, 2016 | -4.79 Mn |
| Mar 31, 2016 | -12.48 Mn |
| Dec 31, 2015 | -14.89 Mn |
| Sep 30, 2015 | -9.54 Mn |
| Jun 30, 2015 | -5.46 Mn |
| Mar 31, 2015 | -10.29 Mn |
| Dec 31, 2014 | 69.69 Mn |
| Sep 30, 2014 | -1.45 Mn |
| Jun 30, 2014 | -21.61 Mn |
| Mar 31, 2014 | -26.58 Mn |
| Dec 31, 2013 | -7.79 Mn |
| Sep 30, 2013 | -5.43 Mn |
| Jun 30, 2013 | -3.41 Mn |
| Mar 31, 2013 | -4.57 Mn |
| Dec 31, 2012 | -6.43 Mn |
| Sep 30, 2012 | -5.40 Mn |
| Jun 30, 2012 | -8.09 Mn |
| Mar 31, 2012 | -8.32 Mn |
| Dec 31, 2011 | -5.91 Mn |
| Sep 30, 2011 | -3.29 Mn |
| Jun 30, 2011 | -1.51 Mn |
| Mar 31, 2011 | 7,000.00 |
| Dec 31, 2010 | 791,000.00 |
| Sep 30, 2010 | 743,000.00 |
| Jun 30, 2010 | 1.16 Mn |